# METIS Innovative

METIS Innovative is a Private Equity based in Miami, United States.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Miami, United States
- **Region:** North America
- **Address:** Miami, FL, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** www.metisinnovative.com
- **LinkedIn:** https://www.linkedin.com/company/metis-innovative

## Regulatory record

- **Reports private funds:** No

## About

METIS Innovative is a physician-founded, patient-focused investment firm improving the lives of people suffering from neurologic illness through neurotechnology. Since 2017 it has invested in promising early-stage medical devices and technology in the neurosciences. It was founded by two prominent neurosurgeons in academic practice and a veteran of capital accrual, with a mission to identify and invest in unique, well positioned companies focused on scientific breakthroughs.

## Sectors

- Digital Health
- Medical Devices
- Neuroscience

## People

- Brian A. Sidman — Founder & Managing Partner
- Dimitri Sigounas, MD — Co-Founder & Managing Partner
- Christopher Kellner, MD — Co-Founder & Managing Partner

## Questions

### Who runs investment decisions at METIS Innovative?

Investment decisions are made by the founding partners: Dr. Dimitri Sigounas, Dr. Christopher Kellner, and Brian Sidman. Sigounas and Kellner are practicing academic neurosurgeons who evaluate the clinical merit of target technologies, while Sidman leads capital formation and deal structuring. This dual clinical-operational investment committee model is central to the firm's sourcing and diligence process.

### How does METIS Innovative source deal flow?

METIS sources through the clinical networks of its physician founders, who encounter neurotechnology innovations through academic medicine, surgical practice, and research collaborations. The firm also leverages its reputation as an early backer of prominent neurotech companies, attracting inbound interest from founders developing brain-computer interfaces, neuromodulation, and neurosurgical devices. No formal scout network or institutional sourcing platform is disclosed.

### What investment stages does METIS Innovative target?

METIS targets seed and early-stage companies. The firm describes its investments as 'promising early stage medical devices and technology in the neurosciences,' and portfolio companies such as Synchron, Proprio, and Fluid Biomed were backed at stages ranging from pre-clinical to early human trials.

### Which sectors does METIS Innovative explicitly avoid?

METIS focuses exclusively on neuroscience and neurotechnology — specifically medical devices, brain-computer interfaces, and digital health platforms for neurological conditions. The firm does not invest in pharmaceuticals, biotechnology outside the CNS space, or therapeutic areas beyond neurology. No investments have been disclosed in non-neuro health sectors.

### Where does the underlying investment capital come from?

The firm does not publicly disclose its limited partner base or the specific source of its investment capital. Co-founder Brian Sidman is described as a 'veteran of capital accrual for investment opportunities,' but the scale, structure, and identity of the firm's funding sources remain undisclosed as of mid-2025.

## Related profiles

- [Metis Capital Management](https://altss.com/profile/metis-capital-management)
- [Metistone Equity Partners](https://altss.com/profile/metistone-equity-partners)

---

Last updated: 2026-08-11T15:07:26.757Z

Canonical page: https://altss.com/profile/metis-innovative

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology